

CLAIMS

1. A nucleic acid having the nucleotide sequence SEQ ID NO:3.
2. A polypeptide encoded by the nucleic acid of claim 1.
- 5 3. A nucleic acid having the nucleotide sequence SEQ ID NO:4.
4. A polypeptide encoded by the nucleic acid of claim 3.
5. A nucleic acid having the nucleotide sequence SEQ ID NO:7.
6. A polypeptide encoded by the nucleic acid of claim 5.
7. An expression construct comprising a nucleic acid having a sequence
10 selected from the group consisting of SEQ ID NOS: 3, 4, and 7.
8. A host cell comprising the expression construct of claim 7.
9. A method of producing a polypeptide, comprising culturing the host cell of
claim 8.
10. An expression construct comprising a portion of a nucleic acid having a
15 portion of sequence selected from the group consisting of SEQ ID NO:3
wherein said portion of said sequence lacks nucleotide sequences that encode
a transmembrane domain of a polypeptide encoded thereby.
11. An expression construct comprising a portion of a nucleic acid having a
20 portion of sequence selected from the group consisting of SEQ ID NO:4
wherein said portion of said sequence lacks nucleotide sequences that encode
a transmembrane domain of a polypeptide encoded thereby.
12. An expression construct comprising a portion of a nucleic acid having a
portion of sequence selected from the group consisting of SEQ ID NO:7
25 wherein said portion of said sequence lacks nucleotide sequences that encode
a transmembrane domain of a polypeptide encoded thereby.
11. A host cell comprising the expression vector of claim 10.

12. A host cell comprising the expression vector of claim 11.
13. A host cell comprising the expression vector of claim 12.
14. A method of producing a soluble receptor fragment, comprising culturing the host cell of claim 11.
- 5 15. A method of producing a soluble receptor fragment, comprising culturing the host cell of claim 12.
16. A method of producing a soluble receptor fragment, comprising culturing the host cell of claim 13.
- 10 17. A soluble receptor fragment, derived from a receptor selected from the group consisting of Edg-1, Edg-3, Edg-5, Edg-6, Edg-8, the Mil receptor, AXOR29, NRG1, SCaMPER and homologs and isoforms thereof.
18. A method of screening for an agent for treating or preventing cardiovascular or cerebrovascular disease, comprising screening a library of compounds for agents that bind a receptor for sphingolipid or a sphingolipid metabolite.
- 15 19. The method of claim 18 wherein said receptor is selected from the group consisting of Edg-1, Edg-3, Edg-5, Edg-6, Edg-8, the Mil receptor, AXOR29, NRG1, SCaMPER and homologs and isoforms thereof.
20. The method of claim 18 wherein said receptor is encoded by SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:7.